April 27, 2011
Mitsubishi Tanabe Pharma Corporation

Summary of the Quality Control Incident

OSAKA, JAPAN, APRIL 27, 2011 — On January 26, 2011, Mitsubishi Tanabe Pharma Corporation (hereinafter, the Company) announced that certain quality tests for shipping were not conducted appropriately at Ashikaga Plant of Mitsubishi Tanabe Pharma Factory, a production subsidiary of the Company. The Company formed promptly "Crisis-management Committee for the Quality Control Incident" comprised eminent persons outside the Company and implemented discussion for investigation of the cause and measures for preventing recurrence. Today, the Company presented "Summary of the Quality Control Incident" regarding direct corrective and improvement measures as well as company wide measures to regain the trust to prevent a recurrence, compiled with the results of inspection for confirming qualities of all the products manufacture in the Company's Group and the proposal issued by "Crisis-management Committee. The summary is available on the Company's website (only in Japanese).

The Company takes it very seriously that we caused concern and trouble to patients, medical professionals and the rest of society during conducting improvement measures, formulated in last June, for administrative action—suspension of business and an order for improvement—from the Minister of Health Labour and Welfare in regard to a violation of the Pharmaceutical Affairs Law concerning the ethical drug Medway Injection, recombinant human serum albumin preparation.

Mitsubishi Tanabe Pharma will never let this happen again, and as a company engaged in the life science, we will do our utmost to regain the trust of the society through stable supply of high-quality pharmaceuticals.

The Company is currently conducting a thorough examination into the impact of the recent disaster on consolidated business performance. The Company will make prompt notifications if any impact of the incident on consolidated business performance should be identified.

<Media enquiry>
Corporate Communications Department
Phone: +81 6-6205-5211